Compositions and methods for treating diabetes

Details Compositions and methods for treating diabetes Compositions and methods for treating diabetes

2002-12-23

2008-03-11

Ungar, Susan (Department: 1642)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

C435S320100, C435S069100, C514S003100, C514S866000

Reexamination Certificate

active

07341869

ABSTRACT:
The present invention provides an isolated population of cells containing an expressible nucleic acid encoding proinsulin containing a proinsulin cleavage site and a glucose-regulated expressible nucleic acid encoding a protease capable of cleaving the proinsulin cleavage site to produce insulin. The invention also provides an isolated population of cells which further express a hexosamine synthetic pathway enzyme. The invention additionally provides vectors containing an expressible nucleic acid encoding proinsulin containing a proinsulin cleavage site and a glucose-regulated expressible nucleic acid encoding a protease capable of cleaving the proinsulin cleavage site to produce insulin. The invention further provides a method of treating or preventing diabetes by implanting into an individual cells coexpressing proinsulin containing a proinsulin cleavage site and a glucose-regulated protease capable of cleaving the proinsulin cleavage site to produce insulin.

REFERENCES:
patent: 5993799 (1999-11-01), Newgard
patent: 6048524 (2000-04-01), Selden et al.
patent: 6348327 (2002-02-01), Gorman et al.
patent: 6352857 (2002-03-01), Alam et al.
patent: WO 92/21756 (1992-12-01), None
patent: WO 95/14785 (1995-06-01), None
patent: WO 95/25547 (1995-09-01), None
patent: WO 96/31242 (1996-10-01), None
patent: WO 96/32489 (1996-10-01), None
patent: WO 96/40175 (1996-12-01), None
patent: WO 97/46590 (1997-12-01), None
Nerlich et al. (Diabetes, Feb. 1998, vol. 47, No. 2, abstract only).
Smeekens et al (PNAS, 1992, 89:8822-8826).
Ali et al., “Preventing gastroepiploic artery spasm: papaverine vs calcium channel blockade,”J. of Surg. Res., 71:41-45 (1997).
Becker et al., “Use of recombinant adenovirus for metabolic engineering of mammalian cells,”Methods in Cell Biol., 43:161-189 (1994).
Dale et al., “A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia,”Blood, 81(10);2496-2502 (1993).
Dale and Hammond, “Cyclic neutropenia: a clinical review,”Blood Reviews, 2:178-185 (1988).
Daniels et al., “Glucose regulation of transforming growth factor-α expression is mediated by products of the hexosamine biosynthesis pathway,”Mol. Endocrinol., 7(8):1041-1048 (1993).
Efrat, S., “Genetic engineering of β-cells for cell therapy of diabetes: cell growth, function, and immunogenicity,”Diabetes Reviews, 4(2):224-234 (1996).
Geary et al., “Gene transfer in baboons using prosthetic vascular grafts seeded with retrovirally transduced smooth muscle cells: a model for local and systemic gene therapy,”Hum. Gene Ther., 5:1211-1216 (1994).
Gros et al., “Regulated production of mature insulin by non-β-cells,”Human Gene Therapy, 8:2249-2259 (1997).
Groskreutz et al., “Genetically engineered proinsulin constitutively processed and secreted as mature, active insulin,”J. Biol. Chem., 269(8):6241-6245 (1994).
Hock et al., “Expression of human adenosine deaminase from various strong promoters after gene transfer into human hematopoietic cell lines,”Blood, 74(2):876-881 (1989).
Hosaka et al., “Arg-X-Lys.Arg-Arg Motif as a signal for precursor cleavage catalyzed by furin within the constitutive secretory pathway,”J. Biol. Chem., 266(19):12127-12130 (1991).
Janeway and Travers, “The immune system, in health and disease,”Immunobiology, pp. 11:23-11:29 (1994).
Kawakami et al., “Subcutaneous xenotransplantation of hybrid artificial pancreas encapsulating pancreatic B cell line (MIN6):functional and histological study,”Cell Transplant, 6(5):541-545 (1997).
Kolodka et al., “Gene therapy for diabetes mellitus in rats by hepatic expression of insulin,”Proc. Natl. Acad. Sci. USA, 92:3293-3297 (1995).
Lejnieks et al., “Granulocyte colony stimulating factor expression from transduced vascular smooth muscle cells provides sustained neutrophil increases in rats,”Hum. Gene Ther., 7:1431-1436 (1996).
Lu et al., “Regulatable production of mature insulin from a hepatocyte cell line: insulin production is up-regulated by cAMP and glucocorticoids, and down-regulated by insulin”(FEBS Letters, vol. 399, pp. 37-42 (1996).
McClain and Crook, “Hexosamines and insulin resistance,”Diabetes, 45:1003-1009 (1996).
McClain et al., “Glucose and glucosamine regulate growth factor gene expression in vascular smooth muscle cells,”Proc. Natl. Acad. Sci. USA, 89:8150-8154 (1992).
McKnight et al., “Molecular cloning, cDNA sequence, and bacterial expression of human glutamine:fructose-6-phosphate amidotransferase,”J. Biol. Chem., 267(35):25208-25212 (1992).
Morgan et al., “Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy,”Nucl. Acids Res., 20(6):1293-1299 (1992).
Naffakh et al, “Sustained delivery of erythropoietin in mice by genetically modified skin fibroblasts,”Proc. Natl. Acad. Sci. USA, 92:3194-3198 (1995).
Newgard, C., “Cellular engineering and gene therapy strategies for insulin replacement in diabetes,”Diabetes, 43:341-350 (1994).
Odagiri et al., Function of the human insulin promoter in primary cultured islet cells,J. Biol. Chem., 271(4):1909-1915 (1996).
Osborne and Miller, “Design of vectors for efficient expression of human purine nucleoside phosphorylase in skin fibroblasts from enzyme-deficient humans,”Proc. Natl. Acad. Sci. USA, 85:6851-6855 (1988).
Osborne et al., “Transduced vascular smooth muscle cells in a canine model of gene therapy,”Clinical Res., 41(2):194A (1993).
Osborne et al., “Gene therapy for long-term expression of erythropoietin in rats,”Proc. Natl. Acad. Sci. USA, 92:8055-8058 (1995).
Osborne et al., “Long-Term Expression of Human Adenosine Deaminase in Mice After Transplantation of Bone Marrow Infected with Amphotropic Retroviral Vectors,”Hum. Gene Ther., 1:31-41 (1990).
Raja et al., “Transcriptional regulation of the human transforming growth factor-α gene,”Mol. Endocrinol., 5(4):514-520 (1991).
Ramesh et al., “High-titer bicistronic retroviral vectors employing foot-and-mouth disease virus internal ribosome entry site,”Nucleic Acids Res., 24(14):2697-2700 (1996).
Sayeski et al., “The murine glutamine:fructose-6-phosphate amidotransferase-encoding cDNA sequence,”Gene, 140:289-290 (1994).
Scharp et al., “Protection of encapsulated human islets implanted without immunosuppression in patients with type I or type II diabetes and in nondiabetic control subjects,”Diabetes, 43:1167-1170 (1994).
Schuppin and Rhodes, “Specific co-ordinated regulation of PC3 and PC2 gene expression with that of preproinsulin in insulin-producing βTC3 cells,”Biochem. J., 313:259-268 (1996).
Smeekens et al., “Proinsulin processing by the subtilisin-related proprotein convertases furin, PC2, and PC3,”Proc. Natl. Acad. Sci. USA, 89:8822-8826 (1992).
Stockschlaeder et al., “L-Histidinol provides effective selection of retrovirus-vector-transduced keratinocytes without impairing their proliferative potential,”Hum. Gene Ther., 2:33-39 (1991).
Stryer, L., “Preproinsulin and proinsulin are the precursors of the active hormone,”Biochemistry, 2nd ed., pp. 847-848 (1981).
Sugiyama et al., “Defective adenoassociated viral-mediated transfection of insulin gene by direct injection into liver parenchyma decreases blood glucose of diabetic mice,”Horm. Metab. Res., 29:599-603 (1997).
Vollenweider et al., “Processing of proinsulin by Furin, PC2, and PC3 in (Co) transfected COS (Monkey Kidney) cells,”Diabetes, 44:1075-1080 (1995).
Walther and Stein, “Cell type specific and inducible promoters for vectors in gene therapy as an approac

Affiliated with

Also associated with

Rating

Compositions and methods for treating diabetes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for treating diabetes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treating diabetes will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3967915